There are convincing evidences that exosomes derived from diverse cancer cell lines, including mesothelioma, breast, and prostate cancer cells, express NKG2D ligands, and thereby downregulate NKG2D expression on NK cells and CD8+ T cells, resulting in impaired cytotoxic effector functions [48–50]. The gene discussed is KLRK1; the disease is prostate cancer.